FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy

Authorized Users Only
1997
Authors
Miljković, Branislava
Pokrajac, Milena
Timotijević, Ivana
Varagić, V.M.
Article (Published version)
Metadata
Show full item record
Abstract
The influence of lithium on fluvoxamine therapeutic efficacy, plasma concentrations and pharmacokinetics was studied in 12 depressed inpatients. Six patients were on fluvoxamine monotherapy and six were on combined fluvoxamine-lithium therapy. The treatment response was determined using 17-item Hamilton Rating Scale for Depression. Blood samples were collected during 48 h after a single dose administration of 100 mg fluvoxamine, and five times at steady state after repeated doses of 100 mg fluvoxamine per day. The evaluation of 17-item Hamilton Rating Scale for Depression Scores showed a significant clinical improvement 2 and 4 weeks after the beginning of the therapy in both groups (p lt 0.01). However, 2 weeks after the administration of the drug(s) had started, significant differences (p lt 0.05) in efficacy between the two treatments in favour of the fluvoxamine-lithium combination were found. Plasma concentrations of fluvoxamine were measured by high-performance liquid chromat...ography. The comparison of the measured concentrations of fluvoxamine showed a similar course of the plasma concentration-time curves in both groups of patients. Pharmacokinetic parameters of fluvoxamine did not show any significant difference on the comparison between the groups. According to the results from this study, it is evident that lithium does not affect plasma concentrations and pharmacokinetics of fluvoxamine in depressed patients on concomitant treatment with these two drugs. However, the effect achieved with the combination was better.

Keywords:
Depression / Fluvoxamine / Interaction / Lithium / Pharmacokinetics
Source:
International Clinical Psychopharmacology, 1997, 12, 4, 207-212
Publisher:
  • Rapid Science Publishers, London

DOI: 10.1097/00004850-199707000-00004

ISSN: 0268-1315

PubMed: 9347381

WoS: A1997XY01900004

Scopus: 2-s2.0-0030866016
[ Google Scholar ]
11
9
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/155
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Miljković, Branislava
AU  - Pokrajac, Milena
AU  - Timotijević, Ivana
AU  - Varagić, V.M.
PY  - 1997
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/155
AB  - The influence of lithium on fluvoxamine therapeutic efficacy, plasma concentrations and pharmacokinetics was studied in 12 depressed inpatients. Six patients were on fluvoxamine monotherapy and six were on combined fluvoxamine-lithium therapy. The treatment response was determined using 17-item Hamilton Rating Scale for Depression. Blood samples were collected during 48 h after a single dose administration of 100 mg fluvoxamine, and five times at steady state after repeated doses of 100 mg fluvoxamine per day. The evaluation of 17-item Hamilton Rating Scale for Depression Scores showed a significant clinical improvement 2 and 4 weeks after the beginning of the therapy in both groups (p  lt  0.01). However, 2 weeks after the administration of the drug(s) had started, significant differences (p  lt  0.05) in efficacy between the two treatments in favour of the fluvoxamine-lithium combination were found. Plasma concentrations of fluvoxamine were measured by high-performance liquid chromatography. The comparison of the measured concentrations of fluvoxamine showed a similar course of the plasma concentration-time curves in both groups of patients. Pharmacokinetic parameters of fluvoxamine did not show any significant difference on the comparison between the groups. According to the results from this study, it is evident that lithium does not affect plasma concentrations and pharmacokinetics of fluvoxamine in depressed patients on concomitant treatment with these two drugs. However, the effect achieved with the combination was better.
PB  - Rapid Science Publishers, London
T2  - International Clinical Psychopharmacology
T1  - The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy
VL  - 12
IS  - 4
SP  - 207
EP  - 212
DO  - 10.1097/00004850-199707000-00004
UR  - conv_4514
ER  - 
@article{
author = "Miljković, Branislava and Pokrajac, Milena and Timotijević, Ivana and Varagić, V.M.",
year = "1997",
abstract = "The influence of lithium on fluvoxamine therapeutic efficacy, plasma concentrations and pharmacokinetics was studied in 12 depressed inpatients. Six patients were on fluvoxamine monotherapy and six were on combined fluvoxamine-lithium therapy. The treatment response was determined using 17-item Hamilton Rating Scale for Depression. Blood samples were collected during 48 h after a single dose administration of 100 mg fluvoxamine, and five times at steady state after repeated doses of 100 mg fluvoxamine per day. The evaluation of 17-item Hamilton Rating Scale for Depression Scores showed a significant clinical improvement 2 and 4 weeks after the beginning of the therapy in both groups (p  lt  0.01). However, 2 weeks after the administration of the drug(s) had started, significant differences (p  lt  0.05) in efficacy between the two treatments in favour of the fluvoxamine-lithium combination were found. Plasma concentrations of fluvoxamine were measured by high-performance liquid chromatography. The comparison of the measured concentrations of fluvoxamine showed a similar course of the plasma concentration-time curves in both groups of patients. Pharmacokinetic parameters of fluvoxamine did not show any significant difference on the comparison between the groups. According to the results from this study, it is evident that lithium does not affect plasma concentrations and pharmacokinetics of fluvoxamine in depressed patients on concomitant treatment with these two drugs. However, the effect achieved with the combination was better.",
publisher = "Rapid Science Publishers, London",
journal = "International Clinical Psychopharmacology",
title = "The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy",
volume = "12",
number = "4",
pages = "207-212",
doi = "10.1097/00004850-199707000-00004",
url = "conv_4514"
}
Miljković, B., Pokrajac, M., Timotijević, I.,& Varagić, V.M.. (1997). The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy. in International Clinical Psychopharmacology
Rapid Science Publishers, London., 12(4), 207-212.
https://doi.org/10.1097/00004850-199707000-00004
conv_4514
Miljković B, Pokrajac M, Timotijević I, Varagić V. The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy. in International Clinical Psychopharmacology. 1997;12(4):207-212.
doi:10.1097/00004850-199707000-00004
conv_4514 .
Miljković, Branislava, Pokrajac, Milena, Timotijević, Ivana, Varagić, V.M., "The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy" in International Clinical Psychopharmacology, 12, no. 4 (1997):207-212,
https://doi.org/10.1097/00004850-199707000-00004 .,
conv_4514 .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceInstitutions/communitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB